This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Greider, B. W. Articles by Franko, A. J. Search for Related Content PubMed PubMed Citation Articles by Greider, B. W. Articles by Franko, A. J.

Recruitment of Noncycling Tumor Cells into Proliferation by Isoproterenol¹

Department of Radiology, Stanford University School of Medicine, Stanford, California 94305

The resistance of tumors to conventional anticancer therapy is partially determined by the fraction of noncycling cells they contain. In several normal tissues, isoproterenol can stimulate cell proliferation. The effect of isoproterenol on the EMT6/St tumor grown both intradermally in BALB/c mice and in vitro as multicell spheroids was investigated. The incorporation of [³H]thymidine (5 µCi/g, 6.7 Ci/mmol) into DNA was determined as a function of time after i.p. injection of isoproterenol (0.15 mg/g). Tissue section autoradiographs of the EMT6 tumors were prepared, and labeling indices were determined. EMT6 spheroids were exposed to isoproterenol and labeled with [³H]thymidine in a manner designed to simulate drug exposure in vivo. In EMT6 tumors, the labeling index rose from a control level of 30% to a peak of 53% at 25 hr; it then declined gradually for the next 30 hr.

This may be interpreted as evidence that cells were recruited into proliferation. In contrast, isoproterenol had minimal effects on EMT6 spheroids, implying that recruitment caused by this drug was not a direct effect on individual cells.

¹ This work was supported by Grants CA03353 and CA10372 from the NIH, Department of Health, Education, and Welfare.

² Present address: Department of Ophthalmology, Veterans Administration Hospital, Sepulveda, Calif. 91343.

³ To whom requests for reprints should be addressed.

⁴ Present address: Radiobiology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada TGG122.

Received 7/10/82. Accepted 12/30/82.